Target intelligence / Profile preview

Potassium voltage-gated channel subfamily H member 6 (KCNH6)

Target
KCNH6
Molecular classification
Ion channel, Voltage-gated potassium channel
01

Overview

Potassium voltage-gated channel subfamily H member 6 (KCNH6) is a pore-forming alpha subunit of a voltage-gated inwardly rectifying potassium channel, belonging to the Eag (ether-à-go-go) related gene family. This large transmembrane protein forms tetrameric potassium-selective channels responsible for regulating ion movement across the membrane in response to changes in membrane voltage, with important roles in cellular excitability, action potential repolarization, and tissue-specific physiological functions such as neurotransmitter release, heart rate regulation, and insulin secretion. It is structurally and functionally related to other family members such as KCNH2 (hERG), which is a well-known antiarrhythmic drug target. Although KCNH6’s detailed disease roles and drug interactions are less well characterized than KCNH2, aberrations are associated with several pathologies, and safety concerns may be inferred due to the functional family’s importance in cardiac and neuronal electrophysiology[1][3][6].

Other names
ERG-2Eag-related protein 2Ether-a-go-go-related gene potassium channel 2HERG2Kv11.2hERG-2erg2voltage-gated inwardly rectifying potassium channel KCNH6voltage-gated potassium channel subunit Kv11.2potassium voltage-gated channel, subfamily H (eag-related), member 6potassium voltage-gated channel subfamily H member 6[1][3][5]
02

Mechanism of action

Blockade/modulation of potassium flux through voltage-gated ion channel; alteration of membrane repolarization kinetics[2][3][6]

03

Biological functions

Ion transportMembrane repolarization during action potentialRegulation of membrane potentialRegulation of neurotransmitter releaseCardiac action potentialCell excitability[2][3][6]
04

Disease associations

CancerCardiovascular diseaseOther neurological and metabolic disorders (e.g., insulin secretion, neuronal excitability, placental choriocarcinoma, primary amebic meningoencephalitis)[3]
05

Safety considerations

Potential for cardiac arrhythmias or other excitability-related adverse effects due to role in membrane repolarization (extrapolated from family member hERG/KCNH2/ERG1)[2][3][6]

Beyond the preview

Go deeper on Potassium voltage-gated channel subfamily H member 6 (KCNH6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potassium voltage-gated channel subfamily H member 6 (KCNH6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call